Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model.


Conditional suicide genes derived from pathogens have been developed to confer drug sensitivity and enhance safety of cell therapy, but this approach is limited by immune responses to the transgene product. We examined a strategy to regulate survival of transferred cells based on induction of apoptosis through oligomerization of a modified human Fas receptor by a bivalent drug (AP1903). Three macaques (Macaca nemestrina) received autologous T cells retrovirally engineered to express a Fas suicide-construct (LV'VFas). High levels of transduced cells were present in blood following cell transfer, but LV'VFas(+) cells declined rapidly after AP1903 administration. A small fraction of LV'VFas(+) cells resisted elimination by AP1903, in part due to insufficient levels of transgene expression in resting T cells, because reactivation of these cells in vitro enhanced sensitivity to AP1903. An immune response to the transgene product was observed, but epitope mapping indicated the response was directed to discrete components of human LV'VFas that were variant with the corresponding macaque sequences. These data demonstrate that chemically induced dimerization can be used to regulate survival of adoptively transferred T cells in vivo.


Citations per Year

386 Citations

Semantic Scholar estimates that this publication has 386 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Berger2004PharmacologicallyRF, title={Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model.}, author={Carolina Berger and C. Anthony Blau and Meei-li Huang and John D. Iuliucci and David C Dalgarno and Jo{\"{e}lle Gaschet and Shelly Heimfeld and Tim Clackson and Stanley R. Riddell}, journal={Blood}, year={2004}, volume={103 4}, pages={1261-9} }